Sanofi Genzyme
500 Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-252-7500
Fax: 617-252-7600
Website: https://www.sanofigenzyme.com/
About Sanofi Genzyme
About Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles about Sanofi Genzyme
-
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
Its Phase III MODIFY study had hoped to find a positive effect of its oral substrate reduction therapy lucerastat on adult patients who have been diagnosed with Fabry disease.
-
Aurion Biotech is focused on curative and restorative treatments for corneal endothelial disease.
-
Sanofi Genzyme to Resume Clinical Trials of Hemophilia Drug Fitusiran with Optimized Dosing Regimen
12/11/2020
Sanofi announced yesterday that they will resume dosing in U.S. clinical trials. They noted that on October 30, they had “voluntarily paused dosing in all ongoing fitusiran clinical studies … to assess reports of non-fatal thrombotic events in patients participating in the Phase III program.” -
Bill Sibold, executive vice president and head of Sanofi Genzyme, is passionate about fomenting programs that increase the diversity of the workforce in his company and the pharmaceutical industry as a whole.
-
Three hemophilia organizations issued a joint statement reporting that Sanofi Genzyme had placed a global dosing hold on its full clinical development program.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
9/9/2020
New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
-
Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
-
Following months of concerns regarding the potential contamination of ranitidine-based products with known carcinogens, the U.S. Food and Drug Administration is asking manufacturers to immediately withdraw all prescription and over-the-counter drugs from the market.
-
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
As Sanofi continues to undergo a planned renovation announced in December, it will do so without four long-time executives.
-
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.